Table of Contents

1 Study Coverage

• 1.1 Neurodegenerative Diseases Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Neurodegenerative Diseases Market Size Growth Rate by Product
  • 1.4.2 NMDA
  • 1.4.3 SSRIs
  • 1.4.4 Dopamine Inhibitors
• 1.5 Market by End User
  • 1.5.1 Global Neurodegenerative Diseases Market Size Growth Rate by End User
  • 1.5.2 Parkinson’s disease
  • 1.5.3 Huntington disease
  • 1.5.4 Amyotrophic Lateral Sclerosis
  • 1.5.5 Alzheimer’s disease
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Neurodegenerative Diseases Market Size
  • 2.1.1 Global Neurodegenerative Diseases Revenue 2014-2025
  • 2.1.2 Global Neurodegenerative Diseases Sales 2014-2025
• 2.2 Neurodegenerative Diseases Growth Rate by Regions
  • 2.2.1 Global Neurodegenerative Diseases Sales by Regions
  • 2.2.2 Global Neurodegenerative Diseases Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Neurodegenerative Diseases Sales by Manufacturers
  • 3.1.1 Neurodegenerative Diseases Sales by Manufacturers
  • 3.1.2 Neurodegenerative Diseases Sales Market Share by Manufacturers
  • 3.1.3 Global Neurodegenerative Diseases Market Concentration Ratio (CR5 and HHI)
• 3.2 Neurodegenerative Diseases Revenue by Manufacturers
  • 3.2.1 Neurodegenerative Diseases Revenue by Manufacturers (2014-2019)
  • 3.2.2 Neurodegenerative Diseases Revenue Share by Manufacturers (2014-2019)
• 3.3 Neurodegenerative Diseases Price by Manufacturers
• 3.4 Neurodegenerative Diseases Manufacturing Base Distribution, Product Types
  • 3.4.1 Neurodegenerative Diseases Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Neurodegenerative Diseases Product Type
  • 3.4.3 Date of International Manufacturers Enter into Neurodegenerative Diseases Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Neurodegenerative Diseases Sales by Product
• 4.2 Global Neurodegenerative Diseases Revenue by Product
• 4.3 Neurodegenerative Diseases Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Neurodegenerative Diseases Breakdown Data by End User

6 North America

• 6.1 North America Neurodegenerative Diseases by Countries
  • 6.1.1 North America Neurodegenerative Diseases Sales by Countries
  • 6.1.2 North America Neurodegenerative Diseases Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Neurodegenerative Diseases by Product
• 6.3 North America Neurodegenerative Diseases by End User

7 Europe

• 7.1 Europe Neurodegenerative Diseases by Countries
  • 7.1.1 Europe Neurodegenerative Diseases Sales by Countries
  • 7.1.2 Europe Neurodegenerative Diseases Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Neurodegenerative Diseases by Product
• 7.3 Europe Neurodegenerative Diseases by End User

8 Asia Pacific

• 8.1 Asia Pacific Neurodegenerative Diseases by Countries
  • 8.1.1 Asia Pacific Neurodegenerative Diseases Sales by Countries
  • 8.1.2 Asia Pacific Neurodegenerative Diseases Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Neurodegenerative Diseases by Product
• 8.3 Asia Pacific Neurodegenerative Diseases by End User

9 Central & South America

• 9.1 Central & South America Neurodegenerative Diseases by Countries
  • 9.1.1 Central & South America Neurodegenerative Diseases Sales by Countries
  • 9.1.2 Central & South America Neurodegenerative Diseases Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Neurodegenerative Diseases by Product
• 9.3 Central & South America Neurodegenerative Diseases by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Neurodegenerative Diseases by Countries
  • 10.1.1 Middle East and Africa Neurodegenerative Diseases Sales by Countries
  • 10.1.2 Middle East and Africa Neurodegenerative Diseases Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Neurodegenerative Diseases by Product
• 10.3 Middle East and Africa Neurodegenerative Diseases by End User

11 Company Profiles

• 11.1 Novartis
  • 11.1.1 Novartis Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Novartis Neurodegenerative Diseases Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Novartis Neurodegenerative Diseases Products Offered
  • 11.1.5 Novartis Recent Development
• 11.2 Merck Serono
  • 11.2.1 Merck Serono Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Merck Serono Neurodegenerative Diseases Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Merck Serono Neurodegenerative Diseases Products Offered
  • 11.2.5 Merck Serono Recent Development
• 11.3 Teva Pharmaceutical
  • 11.3.1 Teva Pharmaceutical Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Teva Pharmaceutical Neurodegenerative Diseases Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Teva Pharmaceutical Neurodegenerative Diseases Products Offered
  • 11.3.5 Teva Pharmaceutical Recent Development
• 11.4 UCB
  • 11.4.1 UCB Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 UCB Neurodegenerative Diseases Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 UCB Neurodegenerative Diseases Products Offered
  • 11.4.5 UCB Recent Development
• 11.5 Pfizer
  • 11.5.1 Pfizer Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Pfizer Neurodegenerative Diseases Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Pfizer Neurodegenerative Diseases Products Offered
  • 11.5.5 Pfizer Recent Development
• 11.6 Biogen Idec
  • 11.6.1 Biogen Idec Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Biogen Idec Neurodegenerative Diseases Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Biogen Idec Neurodegenerative Diseases Products Offered
  • 11.6.5 Biogen Idec Recent Development
• 11.7 Bayer Schering Pharma AG
  • 11.7.1 Bayer Schering Pharma AG Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Bayer Schering Pharma AG Neurodegenerative Diseases Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Bayer Schering Pharma AG Neurodegenerative Diseases Products Offered
  • 11.7.5 Bayer Schering Pharma AG Recent Development
• 11.8 Boehringer Ingelheim
  • 11.8.1 Boehringer Ingelheim Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Boehringer Ingelheim Neurodegenerative Diseases Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Boehringer Ingelheim Neurodegenerative Diseases Products Offered
  • 11.8.5 Boehringer Ingelheim Recent Development
• 11.9 Addex Pharmaceutical
  • 11.9.1 Addex Pharmaceutical Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Addex Pharmaceutical Neurodegenerative Diseases Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Addex Pharmaceutical Neurodegenerative Diseases Products Offered
  • 11.9.5 Addex Pharmaceutical Recent Development
• 11.10 Amarin
  • 11.10.1 Amarin Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Amarin Neurodegenerative Diseases Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Amarin Neurodegenerative Diseases Products Offered
  • 11.10.5 Amarin Recent Development
• 11.11 AstraZeneca
• 11.12 Asubio Pharmaceutical
• 11.13 Bial
• 11.14 Alector
• 11.15 Yumanity Therapeutics
• 11.16 Eisai
• 11.17 H.Lundbeck A/S
• 11.18 Jiangsu Hansoh Pharmaceutical
• 11.19 Yangtze River Pharmaceutical Group
• 11.20 Chongqing Zein Pharmaceutical

12 Future Forecast

• 12.1 Neurodegenerative Diseases Market Forecast by Regions
  • 12.1.1 Global Neurodegenerative Diseases Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Neurodegenerative Diseases Revenue Forecast by Regions 2019-2025
• 12.2 Neurodegenerative Diseases Market Forecast by Product
  • 12.2.1 Global Neurodegenerative Diseases Sales Forecast by Product 2019-2025
  • 12.2.2 Global Neurodegenerative Diseases Revenue Forecast by Product 2019-2025
• 12.3 Neurodegenerative Diseases Market Forecast by End User
• 12.4 North America Neurodegenerative Diseases Forecast
• 12.5 Europe Neurodegenerative Diseases Forecast
• 12.6 Asia Pacific Neurodegenerative Diseases Forecast
• 12.7 Central & South America Neurodegenerative Diseases Forecast
• 12.8 Middle East and Africa Neurodegenerative Diseases Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Neurodegenerative Diseases Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Neurodegenerative diseases are becoming increasingly prevalent due to an aging population, but this diverse therapy area remains largely untreatable with current therapies. Neurodegenerative diseases are characterized by neuronal death within the brain and/or central nervous system (CNS), leading to progressive decline in functional neurological capacities. It has a devastating effect on quality of life and independence, often requiring full-time care during the later disease stages.
The global Neurodegenerative Diseases market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Neurodegenerative Diseases market based on company, product type, end user and key regions.

This report studies the global market size of Neurodegenerative Diseases in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Neurodegenerative Diseases in these regions.
This research report categorizes the global Neurodegenerative Diseases market by top players/brands, region, type and end user. This report also studies the global Neurodegenerative Diseases market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Novartis
Merck Serono
Teva Pharmaceutical
UCB
Pfizer
Biogen Idec
Bayer Schering Pharma AG
Boehringer Ingelheim
Addex Pharmaceutical
Amarin
AstraZeneca
Asubio Pharmaceutical
Bial
Alector
Yumanity Therapeutics
Eisai
H.Lundbeck A/S
Jiangsu Hansoh Pharmaceutical
Yangtze River Pharmaceutical Group
Chongqing Zein Pharmaceutical

Market size by Product
NMDA
SSRIs
Dopamine Inhibitors
Market size by End User
Parkinson’s disease
Huntington disease
Amyotrophic Lateral Sclerosis
Alzheimer’s disease

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Neurodegenerative Diseases market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Neurodegenerative Diseases market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Neurodegenerative Diseases companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Neurodegenerative Diseases submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Neurodegenerative Diseases are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Neurodegenerative Diseases market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.